Presentation is loading. Please wait.

Presentation is loading. Please wait.

The nexus of metabolic changes contributing to reduced plasma glucose and adiposity following inhibition of SGLT2 Thomas and Cherney (2018) Diabetologia.

Published byΜατθάν Αλεβίζος Modified over 6 years ago

Similar presentations

Presentation on theme: "The nexus of metabolic changes contributing to reduced plasma glucose and adiposity following inhibition of SGLT2 Thomas and Cherney (2018) Diabetologia."— Presentation transcript:

1 The nexus of metabolic changes contributing to reduced plasma glucose and adiposity following inhibition of SGLT2 Thomas and Cherney (2018) Diabetologia DOI /s © Springer-Verlag GmbH Germany, part of Springer Nature 2018

2 Physiological mechanisms implicated in changes in renal function following inhibition of SGLT2
Thomas and Cherney (2018) Diabetologia DOI /s © Springer-Verlag GmbH Germany, part of Springer Nature 2018

3 Renal outcomes in the EMPA-REG OUTCOME trial and CANVAS
Empagliflozin Canagliflozin Thomas and Cherney (2018) Diabetologia DOI /s © Springer-Verlag GmbH Germany, part of Springer Nature 2018

Download ppt "The nexus of metabolic changes contributing to reduced plasma glucose and adiposity following inhibition of SGLT2 Thomas and Cherney (2018) Diabetologia."

Similar presentations

140 130 120 110 100 Effect of SGLT-2 inhibitors is different from that of carbohydrate restriction Although restriction of carbohydarate reduces post-prandial.

Effect of SGLT-2 inhibitors is different from that of carbohydrate restriction Although restriction of carbohydarate reduces post-prandial.
Diabetes and CKD- The update

Diabetes and CKD- The update
Mikhail Kosiborod, MD Professor of Medicine (Cardiology)

Mikhail Kosiborod, MD Professor of Medicine (Cardiology)
Cardiovascular Challenges in Diabetes

Cardiovascular Challenges in Diabetes
EMPA-REG OUTCOME: The Endocrinologist's Point of View

EMPA-REG OUTCOME: The Endocrinologist's Point of View
EMPA-REG OUTCOME: The Endocrinologist's Point of View

EMPA-REG OUTCOME: The Endocrinologist's Point of View
Mancia and Grassi (2018) Diabetologia DOI /s

Mancia and Grassi (2018) Diabetologia DOI /s
Empagliflozin (Jardiance®)

Empagliflozin (Jardiance®)
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Elevated levels of various circulating amino acids (AAs) predict the development of Type 2 diabetes. In one prospective study, three branched-chain AAs.

Elevated levels of various circulating amino acids (AAs) predict the development of Type 2 diabetes. In one prospective study, three branched-chain AAs.
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?
New Data on the Safety of SGLT2 Inhibitors

New Data on the Safety of SGLT2 Inhibitors
SGLT2 Inhibitors: What Do the Data Mean for My Patients?

SGLT2 Inhibitors: What Do the Data Mean for My Patients?
Ghrelin—a new player in glucose homeostasis?

Ghrelin—a new player in glucose homeostasis?
Updates on CVOT Data and Clinical Comparisons That Matter

Updates on CVOT Data and Clinical Comparisons That Matter
Global Projections for Diabetes:

Global Projections for Diabetes:
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
CV Risk Management in T2DM: What Did We Learn From EASD 2016?

CV Risk Management in T2DM: What Did We Learn From EASD 2016?
Updates on Outcomes for Novel T2D Therapies

Updates on Outcomes for Novel T2D Therapies

Similar presentations

Ads by Google